Nephromag (Buffered Phosphate Solution | Mertiatide)

Buffered Phosphate Solution, the active ingredient in Nephromag, is a phosphate replacement solution presented as a sterile intravenous solution for infusion use. It is employed to correct phosphate deficiency in patients with renal impairment, those undergoing dialysis, or individuals at risk of hypophosphatemia. GNH USA supplies Nephromag as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide.

Nephromag provides intravenous phosphate repletion for conditions affecting phosphate balance. - Hypophosphatemia: restores serum phosphate levels in patients with low phosphate. - Renal dialysis: supplies phosphate in dialysis fluid to maintain electrolyte homeostasis. - Peri‑operative care: delivers phosphate during major surgery to prevent metabolic disturbances.

Nephromag may be associated with a range of infusion‑related reactions.

Common Side Effects: - Hyperphosphatemia: elevated serum phosphate levels. - Infusion site pain or erythema. - Nausea or vomiting. - Mild hypotension during rapid administration. - Transient calcium reduction. - Electrolyte imbalance (e.g., potassium shift).

Serious or Rare Side Effects: - Severe hyperphosphatemia leading to calcium‑phosphate precipitation. - Anaphylactic or severe allergic reaction. - Cardiac arrhythmias secondary to electrolyte disturbances. - Metabolic acidosis in susceptible patients.

Nephromag requires careful monitoring and patient assessment before and during therapy. - Serum phosphate monitoring: check levels before infusion and periodically thereafter. - Calcium balance: assess calcium levels to avoid precipitation risk. - Renal function: evaluate kidney function, especially in patients with chronic kidney disease. - Contraindications: avoid in patients with known hyperphosphatemia or severe hypercalcemia. - Infusion rate: administer at the rate recommended by the prescriber to reduce infusion reactions. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Nephromag can interact with other agents that affect calcium or phosphate metabolism.

Major Interactions (Avoid): - Calcium‑containing IV solutions: risk of calcium‑phosphate precipitation. - Vitamin D analogues: may exacerbate hypercalcemia. - Aluminum‑containing antacids: reduce phosphate absorption.

Moderate Interactions (Monitor Closely): - Loop diuretics: may increase calcium excretion. - ACE inhibitors or ARBs: monitor renal function and electrolytes. - Parathyroid hormone analogues: adjust phosphate dosing as needed.